Offer - Urjas Oil for just ₹ 1 X
Rapilif D 8/0.5 Combipack is a commercial drug that is prescribed in the form of Capsule. Rapilif D 8/0.5 Combipack also has some secondary and off-label uses. These are listed below.
The right dosage of Rapilif D 8/0.5 Combipack depends on the age, gender, and medical history of the patient. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
Apart from the aforementioned side effects, Rapilif D 8/0.5 Combipack can also lead to other problems, which have been listed below. Usually, these side effects of Rapilif D 8/0.5 Combipack go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Rapilif D 8/0.5 Combipack's effect is Severe during pregnancy and Severe for lactating mothers. In addition, Rapilif D 8/0.5 Combipack's effects on the liver, heart and kidney are discussed below in the Rapilif D 8/0.5 Combipack related warnings section.
Individuals suffering from medical conditions like Kidney Disease, Liver Disease must refrain from the use of Rapilif D 8/0.5 Combipack since this can cause severe adverse effects. Other conditions have been mentioned below in the Rapilif D 8/0.5 Combipack contraindications section.
Additionally, Rapilif D 8/0.5 Combipack may also adversely react with other medicines. A complete list of these interactions is given below.
In addition to the above precautions for Rapilif D 8/0.5 Combipack, it is important to know that it is safe while driving, and is habit-forming.
Rapilif D 8/0.5 Combipack is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Male) |
|
Geriatric |
|
Is the use of Rapilif D 8/0.5 Combipack safe for pregnant women?
Rapilif D should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Rapilif D 8/0.5 Combipack safe during breastfeeding?
Rapilif D may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Rapilif D 8/0.5 Combipack on the Kidneys?
Using Rapilif D does not have any harmful effects on kidneys.
What is the effect of Rapilif D 8/0.5 Combipack on the Liver?
There may be an adverse effect on the liver after taking Rapilif D. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Rapilif D 8/0.5 Combipack on the Heart?
Rapilif D is completely safe for the heart.
If you are suffering from any of the following diseases, you should not take Rapilif D 8/0.5 Combipack unless your doctor advises you to do so -
Is this Rapilif D 8/0.5 Combipack habit forming or addictive?
Rapilif D 8/0.5 Combipack does not cause addiction.
Interaction between Food and Rapilif D 8/0.5 Combipack
Due to a lack of research, nothing can be said about the consequences of taking Rapilif D 8/0.5 Combipack together with food.
Interaction between Alcohol and Rapilif D 8/0.5 Combipack
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Rapilif D 8/0.5 Combipack.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rapaflo® (silodosin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1137-1138
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 476-477
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 303
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Avodart® (dutasteride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Jalyn (dutasteride and tamsulosin hydrochloride)